Skip to main content

Parkinson Disease Psychosis

Neurology
5
Pipeline Programs
7
Companies
6
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 7 programs with unclassified modality

Neurology is a $26.9B market dominated by a single blockbuster anticoagulant (ELIQUIS), representing a mature but consolidating therapeutic area.

$26.9B marketMature→ Stable30 products15 companies

Key Trends

  • Extreme market concentration: 68% of spending driven by one FXa inhibitor product
  • Psychiatric and migraine therapies emerging as secondary growth drivers
  • High clinical trial activity (8,279 trials) signals continued pipeline development

Career Verdict

Neurology offers solid career stability with good hiring demand, but limited upside growth—best suited for professionals seeking established market positions rather than emerging-area innovation.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#1ELIQUISStable
$18.3B
Bristol Myers Squibb·Launch15.0yr
$1.8B
#3BRILINTAStable
$692M
AstraZeneca·Peak10.2yr
#4NUPLAZIDStable
$596M
$530M
Johnson & Johnson·Peak15.6yr

Drug Class Breakdown

FXa Inhibitors (anticoagulant)
$18.3B(68%)

market-defining single product

Dopamine/Serotonin Antagonists (psychiatric)
$2.4B(9%)

stable mature class

P2Y12 Receptor Antagonists (antiplatelet)
$692M(3%)

niche but stable

5-HT2A Inverse Agonists (psychiatric)
$596M(2%)

specialty indication focus

CGRP Receptor Antagonists (migraine)
$931M(3%)

emerging growth segment

Immunomodulators (MS)
$747M(3%)

stable with LOE risk

Other mechanisms
$2.6B(10%)

diverse small products

Career Outlook

Stable

Neurology represents a mature, cash-generative market with limited growth tailwinds but strong hiring stability. The dominance of ELIQUIS creates a bifurcated career landscape: high-opportunity positions in emerging segments (CGRP antagonists, psychiatric therapeutics) and commoditized roles in anticoagulant franchises. Job availability is solid but growth expectations should be tempered relative to oncology or immunology.

Breaking In

Entry-level professionals should target clinical operations or commercial support roles at J&J, AstraZeneca, or Sanofi to build domain expertise in neurology disease states and competitive dynamics.

For Experienced Professionals

Experienced professionals should prioritize emerging mechanism roles (CGRP, tau-targeting programs) or pivot to medtech/neurotech (Stryker, Medtronic) to capture higher growth and salary potential than traditional pharma incumbents.

In-Demand Skills

Medical Science Liaisons (MSL) for specialist engagementClinical trial operations expertisePsychiatric/neurodegenerative disease educationRegulatory affairs (given patent cliff activity)Commercial strategy around branded/generic transitions

Best For

Medical Science LiaisonCommercial Brand Manager (anticoagulant/psychiatric franchises)Clinical Operations ManagerRegulatory Affairs SpecialistClinical Development Manager (CGRP/immunomodulator pipelines)

Hiring Landscape

$100K-$199K

Neurology shows moderate but distributed hiring across pharma and medtech employers, with 4,186 total jobs listed. Commercial functions lead (947 roles, $169K avg), followed by clinical operations (467 roles, $132K avg), indicating bias toward commercialization over R&D. Takeda leads external hiring (762 jobs) with strong representation in contract research and CRO spaces.

4,186
Open Roles
5
Companies Hiring
5
Departments

Top Hiring Companies

762Growing
434Stable
302Stable

By Department

Commercial(23%)
$169K
Clinical Operations(11%)
$132K
Engineering(8%)
$199K
IT(4%)
$100K
Manufacturing(3%)
$170K

Commercial and clinical operations roles dominate, offering stable mid-career positions; engineering roles command premium salaries ($199K), suggesting strong device/neurotech hiring pockets.

Competitive Landscape

7 companies ranked by most advanced pipeline stage

AgeneBio
AgeneBioMD - Baltimore
1 program
1
AGB101Phase 21 trial
Active Trials
NCT05824728Recruiting30Est. Sep 2026
Otsuka
OtsukaJapan - Tokushima
1 program
1
SEP-363856Phase 21 trial
Active Trials
NCT02969369Completed39Est. Apr 2020
1ST Biotherapeutics
1ST BiotherapeuticsKorea - Gyeonggi
1 program
1
FB418Phase 1
BioTherapeutics Inc
BioTherapeutics IncVA - Blacksburg
1 program
1
FB418Phase 11 trial
Active Trials
NCT05995782Recruiting64Est. Dec 2024
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
SaracatinibPhase 1Small Molecule1 trial
Active Trials
NCT03661125Unknown30Est. Sep 2021
Acadia Pharmaceuticals
2 programs
Real-world non-interventionalN/A
Real-world, non-interventionalN/A1 trial
Active Trials
NCT03152292Terminated764Est. Mar 2021
Vanda Pharmaceuticals
Vanda PharmaceuticalsWASHINGTON, DC
1 program
IloperidonePHASE_21 trial
Active Trials
NCT05344365Withdrawn0Est. Nov 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AgeneBioAGB101
Vanda PharmaceuticalsIloperidone
OtsukaSEP-363856
BioTherapeutics IncFB418
AstraZenecaSaracatinib
Acadia PharmaceuticalsReal-world, non-interventional

Clinical Trials (6)

Total enrollment: 927 patients across 6 trials

Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis

Start: Sep 2023Est. completion: Sep 202630 patients
Phase 2Recruiting

A Study to Evaluate Iloperidone for the Treatment of Parkinson's Disease Psychosis

Start: Jun 2022Est. completion: Nov 20230
Phase 2Withdrawn

A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis

Start: Dec 2016Est. completion: Apr 202039 patients
Phase 2Completed

A Phase 1, SAD and MAD Study to Evaluate the Safety and Tolerability of FB418

Start: Dec 2023Est. completion: Dec 202464 patients
Phase 1Recruiting

SRC Inhibition as a Potential Target for Parkinson's Disease Psychosis

Start: Apr 2019Est. completion: Sep 202130 patients
Phase 1Unknown
NCT03152292Acadia PharmaceuticalsReal-world, non-interventional

The INSYTE (Management of Parkinson's Disease Psychosis in Actual Practice) Study

Start: Mar 2017Est. completion: Mar 2021764 patients
N/ATerminated

Related Jobs in Neurology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 actively recruiting trials targeting 927 patients
7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.